secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-039837
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences reports FY2024 net loss of $61.9M; pipeline milestones for 2025
-------------------------------------------------------------------------------

- Cash and marketable securities $262.1M as of Dec 31, 2024; expected to fund operations into mid-2027.
- Phase 2 Avail trial of canvuparatide in hypoparathyroidism fully enrolled (64 patients); topline results expected Q3 2025.
- MBX 1416 Phase 1 trial positive; Phase 2 in post-bariatric hypoglycemia to start 2H 2025.
- IND submission for MBX 4291 in obesity anticipated in Q2 2025.
- Net loss for FY2024 was $61.9M vs $32.6M in FY2023, driven by increased R&D and G&A costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025039837/0000950170-25-039837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025039837/mbx-20250317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-039837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer